Dr. Raid Aljumaily
Claim this profileUniversity of Oklahoma Health Sciences Center
About Raid Aljumaily
Education:
Graduated with an MD from the University of Baghdad College of Medicine, Iraq, in 2009.
Completed a Residency in Internal Medicine at the University of Oklahoma Health Sciences Center in 2016.
Finished a Fellowship in Hematology/Oncology at the University of Oklahoma Health Sciences Center in 2019.
Experience:
Has been serving as an Assistant Professor of Medicine at the University of Oklahoma Health Sciences Center since 2019.
Specializes in hematologic malignancies, lymphoma, and myelodysplastic syndromes.
Area of expertise
Lung Cancer
Raid Aljumaily has run 21 trials for Lung Cancer. Some of their research focus areas include:
Non-Small Cell Lung Cancer
Raid Aljumaily has run 14 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Affiliated Hospitals
University Of Oklahoma Health Sciences Center
Cancer Centers Of Southwest Oklahoma Research
Clinical Trials Raid Aljumaily is currently running
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting
2 awards
Phase 3
31 criteria
IMC-F106C Combinations
for Solid Cancers
This trial tests IMC-F106C, a treatment that helps the immune system target and kill cancer cells in adults with advanced cancers. It guides immune cells to attack cancer cells more effectively.
Recruiting
1 award
Phase 1 & 2
More about Raid Aljumaily
Clinical Trial Related
8 years of experience running clinical trials · Led 26 trials as a Principal Investigator · 14 Active Clinical Trials
Treatments Raid Aljumaily has experience with
- Carboplatin
- Pembrolizumab
- Pemetrexed
- Nivolumab
- Atezolizumab
- Paclitaxel
Breakdown of trials Raid Aljumaily has run
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Raid Aljumaily specialize in?
Raid Aljumaily focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Raid Aljumaily currently recruiting for clinical trials?
Yes, Raid Aljumaily is currently recruiting for 14 clinical trials in Oklahoma City Oklahoma. If you're interested in participating, you should apply.
Are there any treatments that Raid Aljumaily has studied deeply?
Yes, Raid Aljumaily has studied treatments such as Carboplatin, Pembrolizumab, Pemetrexed.
What is the best way to schedule an appointment with Raid Aljumaily?
Apply for one of the trials that Raid Aljumaily is conducting.
What is the office address of Raid Aljumaily?
The office of Raid Aljumaily is located at: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104 United States. This is the address for their practice at the University of Oklahoma Health Sciences Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.